

17 January 2025

ASX Announcement

1H FY25 Trading Result (unaudited)

PolyNovo Limited (**PolyNovo** or **Company**) is pleased to provide indicative trading results for 1H FY25.

Highlights:

- U.S. sales of **A\$41.2m up 27.9%** on STLY **A\$32.2m**
- Rest of World sales of **A\$12.9m up 28.6%** on STLY **A\$10.0m** including strong performances in UK/I, Spain, Germany, Turkey and Hong Kong. First sales were made in Malta, Portugal and Peru.
- Total group revenue including BARDA of **A\$59.9m up 22.8%** on STLY **A\$48.8m**

The Company intends to disclose the audited 1H FY25 results on 24 February 2025.

Chief Executive Officer, Swami Raote said: *“As we expand NovoSorb platform and leadership beyond difficult burns to a vast Plastic & Reconstructive Surgery space, we are healing patients and impacting positive outcomes more than twice as fast as revenue growth. We continue to be grateful to our Clinicians and our People in helping us innovate across multiple indications, while delivering meaningfully differentiated patient outcomes across spectrum of Plastic & Reconstructive ladder.*

Additionally, we had a successful meeting with FDA during which they agreed that we have sufficient data to submit an application for PMA approval. We are in the process of compiling all the material needed for submission.”

This announcement has been authorised by PolyNovo Company Secretary, Lior Harel.

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care that designs, develops, and manufactures dermal regeneration solutions (NovoSorb® BTM, NovoSorb® MTX) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information see polynovo.com

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

Further information:

David Williams
Chairman
Mobile: + 61 414 383 593

Swami Raote
CEO
Mobile: +61 3 8681 4050